Pramipexole dihydrochloride hydrate

SKU: orb1300317

Description

Pramipexole dihydrochloride hydrate, a non-ergot dopamine agonist, is the hydrochloride salt form of the benzothiazole derivative pramipexole. It selectively activates D2 and D3 dopamine receptors in brain regions like the striatum. This compound is widely used in in vitro and in vivo research for studying Parkinson's disease, restless legs syndrome, and dopaminergic signaling pathways.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 191217-81-9
• MW: 302.26
• Purity: 99.68%
• Formula: C₁₀H₁₇N₃S·2HCl·H₂O
• SMILES: O.Cl.CCCN[C@H]1CCc2c(C1)sc(N)n2.Cl
• Target: Dopamine Receptor
• Solubility: DMSO:3.46 mg/mL (11.45 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (3.31 mM);H2O:55 mg/mL (181.96 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  D2 receptor:3.9 nM (Ki)|D4 receptor:1.3 nM (Ki)|D2 receptor:2.2 nM (Ki)|D3 receptor:0.5 nM (Ki)
• In Vivo:
  Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited by the D3 receptor antagonist, U-99194 A, or the D2 receptor antagonist, raclopride.Pramipexole also protected MES23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neuroprotective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduced the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration-dependently inhibited the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged.
• In Vitro:
  Pramipexole (4-100 mM) significantly attenuated DA- or L-DOPA-induced cytotoxicity and apoptosis, an effect that was not inhibited by the D3 receptor antagonist, U-99194 A, or the D2 receptor antagonist, raclopride.Pramipexole also protected MES23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. cytotoxicity.Pramipexole effectively inhibited melanin formation.Pramipexole was neuroprotective against nigrostriatal dopamine neurons in hypoxic-ischemic and methamphetamine models. When incubated with SH-SY5Y cells and perfused into rat striatum, Pramipexole reduced the level of oxygen radicals produced by methylpyridinium ion (MPP+).Pramipexole also concentration-dependently inhibited the opening of mitochondrial transporter pore induced by calcium, phosphate, or MPP+. Pramipexole dose Pramipexole dose-dependently decreased dopamine metabolite levels, while striatal dopamine levels remained unchanged.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Parkinson's, Mirapex, middle, neuroprotection, neurological, occlusion, inhibit, Inhibitor, legs, D3, D2S, D2L, D4, disease, Dopamine Receptor, Dopamine, DopamineReceptor, cerebral, artery, syndrome, transient, RLS, restless, Pramipexole dihydrochloride Hydrate, Pramipexole dihydrochloride hydrate, Pramipexole 2HCl, Pramipexole 2HCl Monohydrate, Pramipexole dihydrochloride, tMCAO, recovery

Compound Identifiers

PubChem CID

166589